Screen for portopulmonary hypertension, especially in liver transplant candidates

Cleveland Clinic Journal of Medicine

Volumn 75, Issue 2, 2008, Pages 121-136

  Swanson, Karen L ^a   Krowka, Michael J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASODILATOR AGENT;

HEART CATHETERIZATION; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; MASS SCREENING; PATHOLOGY; PORTAL HYPERTENSION; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; THROMBOSIS; VASOCONSTRICTION;

HEART CATHETERIZATION; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER DISEASES; LIVER TRANSPLANTATION; MASS SCREENING; PULMONARY ARTERY; RISK FACTORS; THROMBOSIS; VASOCONSTRICTION; VASODILATOR AGENTS;

EID: 40949147479     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.75.2.121     Document Type: Review

References (54)

1. Rodriguez-Roisin R, Krowka MJ, Hervé P, Fallon MB; ERS Task Force Pulmonary-Hepatic Vascular Disorders (PHD) Scientific Committee. Pulmonary-hepatic vascular disorders (PHD). Eur Respir J 2004; 24:861-880.
2. Krowka MJ, Swanson KL, Frantz RR et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006, 44:1502-1510.
3. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43:5S-12S.
4. Hadengue A, Benhayoun MK, Lebrec D, et al. Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics. Gastroenterology 1991; 100:520-528.
5. Krowka MJ, Plevak DJ, Findlay JY, et al. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transplant 2000; 6:443-450.
6. Benjaminov FS, Prentice M, Sniderman KW, et al. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut 2003; 52:1355-1362.
7. McDonnell PJ, Toye PA, Hutchins GM. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127:437-441.
8. Cheng EY, Woehlck H. Pulmonary artery hypertension complicating anesthesia for liver transplantation. Anesthesiology 1992; 77:375-378.
9. Castro M, Krowka MJ, Schroeder DR, et al. Frequency and clinical implications of increased pulmonary artery pressures in liver transplantation. Mayo Clin Proc 1996; 71:543-551.
10. Ramsay MA, Simpson BR, Nguyen AT, et al. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg 1997; 3:494-500.
11. Kiely DG, Cargill RI, Struthers AD, et al. Cardiopulmonary effects of endothelin-1 in man. Cardiovasc Res 1997; 33:378-386.
12. Panos RJ, Baker SK. Mediators, cytokines, and growth factors in liver-lung interactions. Clin Chest Med 1996; 17:151-169.
13. Higgenbottam T. Pathophysiology of pulmonary hypertension. Chest 1994; 105:7S-12S.
14. Krowka MJ. Hepatopulmonary syndrome and portopulmonary hypertension: distinction and dilemmas. Hepatology 1997; 25:1282-1284.
15. Hongqun L, Lee SS. Cardiopulmonary dysfunction in cirrhosis. Hepatology 2000; 14:600-608.
16. Lebrec D, Brenot F, Simonneau G, et al. Pulmonary arterial hypertension in portal hypertension. Eur Respir J 1998; 11:1153-1166.
17. Herve P. Lebrec D, Brenot F, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11:1153-1166.
18. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925-1932.
19. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461-1468.
20. Edwards B, Weir K. Edwards WD, et al. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987; 10:1233-1238.
21. Ramsay MAE, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transplant Surg 1997; 3:494-500.
22. Trembath RC. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia N Engl J Med 2001; 345:325-334.
23. Leuckte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004, 43:764-770.
24. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echo-cardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transplant 2000; 6:453-458.
25. Colle IO, Moreau R, Godinho E, et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37:401-409.
26. Provencher S, Herve P. Jais X, et al. Deleterious effects of beta-blockers on exercise capacity and hemodynamics in patients with portopulmonary hypertension. Gastroenterology 2006; 130:120-126.
27. Swanson KL, McGoon MD, Krowka MJ. Survival in patients with portopulmonary hypertension [abstract]. Am J Respir Crit Care Med 2003; 167:A693.
28. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63:604-616.
29. Krowka MJ, Frantz RP McGoon MD, et al. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999; 30:641-648.
30. Kähler CM, Graziadei I, Wiedermann CJ, Kneussl MP, Vogel W. Successful use of continuous intravenous prostacyclin in a patient with severe portopulmonary hypertension. Wien Klin Wochenschr 2000; 112:637-640.
31. Sussman N, Kaza V, Barshes N, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006; 6:2177-2182.
32. Findlay JY, Plevak DJ, Krowka MJ, et al. Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension. Liver Transplant Surg 1999; 5:381-387.
33. Rubin LJ, Roux S. Bosentan: a dual endothelin receptor antagonist. Expert Opin Invest Drugs 2002; 11:991-1002.
34. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69:223-231.
35. Hinterhuber L, Graziadei IW, Kahler CM, et al. Endothelin-receptor anatgonist treatment of portopulmonary hypertension. Clin Gastroenterol Hepatol 2004; 2:1039-1042.
36. Clift PF, Townend JN, Bramhall S. et al. Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan. Transplantation 2004; 77:1774-1775.
37. Halank M, Miehlke S, Hoeffken G, et al. Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension. Transplantation 2004; 77:1775-1776.
38. Kuntzen C, Gulberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005; 128:164-168.
39. Watanabe H, Ohashi K, Takeuchi K, et al. Sildenafil for primary and secondary pulmonary hypertension. Clin Pharmacol Ther 2002; 71:398-402.
40. Michelakis E, Tymchak W, Lien D, et al. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002; 105:2398-2403.
41. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonarl hypertension: a randomised controlled trial. Lancet 2002; 360:895-900.
42. Makisalo H, Koivusalo A, Vakkuri A, et al. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transplant 2004; 10:945-950.
43. Reichengerger F, Voswinckel R, Steveling E, et al. Sildenafil treatment for portopulmonary hypertension. Eur Respir J 2006; 28:563-567.
44. Krowka MJ, Swanson KL. How should we treat portopulmonary hypertension? Eur Respir J 2006; 28:466-40.
45. Kawut SM, Taichman DB, Ahya VN, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transplant 2005; 11:1107-1111.
46. Krowka MJ, Mandell MS, Ramsay MA, et al. Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. Liver Transplant 2004; 10:174-182.
47. Sulica R, Emre S, Poon M. Medical management of porto-pulmonary hypertension and right heart failure prior to living-related liver transplantation. Congest Heart Fail 2004; 10:192-194.
48. De Wolf AM, Begliomini B, Gasior TA, et al. Right ventricular function during orthotopic liver transplantation. Anesthes Analges 1993; 76:562-568.
49. Csete M. Intraoperative management of liver transplant patients with pulmonary hypertension. Liver Transplant Surg 1997; 3:454-455.
50. Acosta F, Sansano T, Palenciano CG, et al. Portopulmonary hypertension and liver transplantation: hemodynamic consequences at reperfusion. Transplant Proc 2005; 37:3865-3866.
51. Taura P, Garcia-Valdecasas JC, Beltran J, et al. Moderate primary pulmonary hypertension in patients undergoing liver transplantation. Anesthes Analges 1996; 83:675-080.
52. Kuo PC, Schroeder RA, Vagelos RH, et al. Volume-mediated pulmonary responses in liver transplant candidates. Clin Transplant 1996; 10:521-527.
53. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991; 17:492-498.
54. Mandell MS, Krowka MJ. Formation of a national database on pulmonary hypertension and hepatopulmonary syndrome in chronic liver disease. Anesthesiology 1997; 87:450-451.